OR WAIT null SECS
© 2023 MJH Life Sciences and BioPharm International. All rights reserved.
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
Process and plasmid design optimization, disposable equipment, and flexible platform processes all play important roles.
Decreasing vein to vein time saves lives.
There is growing pressure for robust and economically scalable viral-vector manufacturing technologies.
Shifts in pharmaceutical packaging have spurred tremendous growth in the pre-filled syringe fill/finish industry.
Considerable efforts have been made over the years to resolve the key issues of stability and delivery of RNA-based therapeutics.
The bio/pharma outsourcing industry continues to be integral in the development and manufacture of medicines.
The trends shaping the growth of the biologics outsourcing industry demand attention.
March 24, 2023
Moderna and Generation Bio have announced a strategic collaboration to develop non-viral genetic medicines.
Curia is collaborating with Corning to advance biopharmaceutical continuous-flow development and manufacturing programs.
A new Interagency Working Group for Bayh-Dole will review the government’s authority to revoke licenses for medical products.
March 23, 2023
The recent document will guide the use of DHT-derived data in regulatory decision-making for drugs and biological products.
TreeFrog Therapeutics is leaping ahead in cell therapies through
resources such as new technologies and investor partnerships.
Advancements in therapeutic modalities are necessitating change in drug delivery to help negate some of the expense of development and manufacturing.
March 22, 2023
Under a new partnership, Invitae and Deerfield Management will harness genetic and clinical testing data from patients to discover potential novel therapeutics for treating rare diseases.
In addition to a new interim president, the company is opening new microbial capacity at its San Antonio facility and has plans to construct a commercial-scale facility in Manhattan, Kan.
The combined solutions are currently available on the market.
The services are based on the company’s PurePrep EasyClean (PEC) orthogonal peptide purification technology.
The decision was based on results from the PROpel Phase III trial.
This approval makes the drug the first and only targeted medicine indicated to treat this population of children in Europe and the United States.